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There is a paucity of high quality clinical trials in glomerular
disease, particularly in non-diabetic kidney disease. The aims
of this review include quantifying the extent of this problem
and exploring reasons for the scarcity of such trials in primary
glomerular disease, with an emphasis on immunoglobulin A
nephropathy, minimal change disease, focal segmental
glomerulosclerosis, and membranous nephropathy in
comparison with the more common diseases of diabetic
nephropathy and lupus nephritis. Reasons for the dearth of
high quality clinical trials in primary glomerular disease
include (1) low prevalence of disease; (2) variability in clinical
presentation; (3) variability in treatment response; (4) lack of
consensus in definitions; (5) difficulty in recruiting patients;
(6) high costs of randomized controlled trials; and (7) lack of
collaborative efforts. To facilitate greater numbers of high
quality clinical trials in glomerular disease, practice guidelines
should establish common classification systems of disease
and common clinical end points, industry and non-industry
sponsored research should find common ground and work
together toward advancing science, and national registries
should be created to encourage collaborations across
institutions and across nations.
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Glomerular disease is an important cause of morbidity and
mortality;1,2 however, with the exception of diabetic nephro-
pathy (DN) there has been a paucity of high quality
randomized controlled trials (RCTs) in this area. The aims
of this review include quantifying the extent of this problem
and exploring reasons for the scarcity of such trials in
glomerular disease. As all etiologies of glomerular disease
could not be reviewed, the following major glomerular
disease entities were chosen as representative: DN, lupus
nephritis (LN), immunoglobulin A nephropathy (IgAN),
minimal change disease (MCD), focal segmental glomerulo-
sclerosis (FSGS), and membranous nephropathy (MN).
CHARACTERISTICS OF PUBLISHED CLINICAL TRIALS IN
GLOMERULAR DISEASE
Medline and the Cochrane Database were searched for
articles written in English and published between 1990 and
2009 using the following keywords: (1) diabetic nephropathy;
diabetic kidney disease; (2) lupus nephritis; lupus nephro-
pathy; lupus glomerulonephritis; (3) Immunoglobulin A
nephropathy; immunoglobulin A nephritis; immunoglobulin
A glomerulonephritis; immunoglobulin A nephropathy;
(4) minimal change disease; minimal change nephrotic
syndrome; lipoid nephrosis; (5) focal segmental glomerulo-
sclerosis; (6) membranous nephropathy; membranous glo-
merular nephropathy; membranous glomerulonephritis.
Additional criteria used to select articles included the
following: (1) articles must have been RCTs or meta-analyses;
(2) post-hoc analyses of RCTs were only included if they
evaluated different end points than the original study; (3) only
studies involving human subjects were included; and
(4) studies which included patients with heterogeneous
etiologies of kidney disease were counted under each individual
category, assuming that the category included a sample size of at
least 10 patients. Among the studies in which the total enrollment
was fewer than 10 patients, designation was attributed solely to
the category with the greatest number of patients.
Using the above criteria, the number of RCTs and meta-
analyses investigating DN, LN, IgAN, MCD, FSGS, and MN
were determined (Figure 1; Supplementary Information for
complete list of studies). As shown, many RCTs and meta-
analyses have been published regarding DN, however, there is
a dearth of studies evaluating non-diabetic glomerular
disease.
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Table 1 shows the total number of patients enrolled and
the mean duration of follow-up (not including washout or
run-in periods) for each of the RCTs. The average number of
subjects enrolled in trials of DN far outweighs the number
enrolled in trials of the other glomerular diseases. The
average duration of follow-up is comparable across all six
diseases represented.
In addition to the relatively small sample sizes and general
shortage of RCTs evaluating non-diabetic glomerular disease,
the quality of many of these trials was poor. For example, a
meta-analysis of 10 RCTs investigating treatments for IgAN
found that none adequately described appropriate randomi-
zation methods, only 2 of 10 had blinding of both
participants and investigators, 5 of 10 reported intention-
to-treat analysis, and 6 of 10 had relevant number of patients
lost at follow-up.3 Furthermore, pertinent data was often
missing from methods and statistical sections. Similarly, in a
meta-analysis of 18 RCTs investigating immunosuppressive
treatment for idiopathic MN, few of the conducted trials
included information on the method of randomization,
reported on blinding of both investigators and participants,
used intention-to-treat analysis, or provided information
regarding completeness of follow-up.4
WHY THE PAUCITY OF CLINICAL TRIALS IN GLOMERULAR
DISEASE?
Low prevalence of disease
One obvious explanation for the scarcity of RCTs in non-
diabetic glomerular disease relates to their infrequent
occurrence. Table 1 shows estimates of the incidence of
DN, LN, IgAN, MCD, FSGS, and MN. The incidence of DN
is approximately 20-fold the incidence of LN and over
40-fold the incidence of the primary glomerular diseases.
Studies of non-diabetic renal disease limited to a single center
or few centers would be unlikely to recruit adequate number
of patients in any reasonable time period.
However, rarity alone does not fully explain the scarcity of
RCTs in glomerular disease. By comparison, Huntington’s
disease and Guillain–Barre syndrome are the two rare
neurological disorders with estimated incidences of 0.3 and
1.3 per 100,000 people per year, respectively, which is similar
to the incidence of the primary glomerular diseases.5,6
However, the number of RCTs performed in the last two
decades, evaluating these two disorders, is 40 and 30,
respectively, which is substantially greater than the corre-
sponding number of trials evaluating the primary glomerular
diseases (with the exception of IgAN). Accordingly, alter-
native explanations for the scarcity of RCTs addressing
glomerular disease must be sought.
Variability in clinical presentation, decision to biopsy, and
decision to initiate therapy
Many primary glomerular diseases are heterogeneous in their
clinical presentation. Some patients present with a gradual
asymptomatic increase in proteinuria, while other patients
present with the sudden onset of massive edema and overt
nephrotic syndrome. Even among patients with the same
type of glomerular histopathology, the degree of proteinuria
may vary and the threshold for starting immunosuppressive
therapy is often controversial. In MN, for example, rates of
spontaneous remission are very high and many patients may
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Figure 1 |Number of RCTs and meta-analyses, by renal
disease category. DN, diabetic nephropathy; FSGS, focal
segmental glomerulosclerosis; IgAN, immunoglobulin A
nephropathy; LN, lupus nephritis; MCD, minimal change disease;
MN, membranous nephropathy; RCT, randomized controlled trial.





Overall 104.2±13.4 79.9±5.7 NA
Diabetic nephropathy (DN) 127.6±19.3 70.0±6.1 54
Lupus nephritis (LN) 68.7±12.2 106.2±17.3 2.8
IgA nephropathy (IgAN) 51.9±4.7 113.3±16.7 1.4
Minimal change disease (MCD) 34.7±5.2 83.1±25.0 0.5
Focal segmental glomerulosclerosis (FSGS) 34.9±5.2 62.7±18.8 1.1
Membranous nephropathy (MN) 49.4±6.0 123.8±29.8 0.7
Abbreviations: NA, not applicable; RCT, randomized controlled trial.
Values indicate mean±s.e.m.
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receive unnecessary treatment. One prospective study of 100
patients with idiopathic MN, who received symptomatic
therapy only (i.e. no glucocorticoid or immunosuppressive
drugs), found an 88% estimated probability of retaining
adequate kidney function at 5 years, and 65% of patients had
complete or partial remission of proteinuria.7 In contrast,
other investigators recommend a wait-and-see policy in
idiopathic MN only for low-risk patients.8,9 Even in these
studies, the indication for immunosuppressive therapy differs
between persistent proteinuria8 and risk-stratifying patients
based on the renal function and urinary excretion of
b2-microglobulin.9 Similarly, controversy exists regarding
the optimal timing of renal biopsy. In IgAN, for example,
some experts advocate for early biopsy in patients with
persistent microhematuria and low-grade proteinuria,
whereas others advocate an initial trial of angiotensin
converting enzyme inhibitor therapy, limiting renal biopsy
only to those patients with a non-satisfactory antiproteinuric
response. Such heterogeneity of disease activity and the
difference in opinion of when to perform biopsy and when to
initiate specific therapy present a challenge to investigators.
Variability in treatment response
An additional challenge to investigators studying glomerular
disease is heterogeneity of response to the treatment. IgAN,
for example, may have a variable response to treatment
depending on the ethnicity and inclusion criteria of study
participants. Although a recent meta-analysis concluded that
the current available evidence does not support the routine
use of mycophenolate mofetil (MMF) in patients with
IgAN,10 this finding was based on only four RCTs. Among
these four RCTs, the two which included predominantly the
Asian patients11,12 found a significant reduction in protei-
nuria with MMF, whereas the two that included caucasian13
and north European patients14 found no reduction in
proteinuria compared with controls. Similarly, although a
meta-analysis3 concluded that cytotoxic agents (cyclopho-
sphamide and azathioprine) are beneficial in IgAN, this
finding was driven almost entirely by a single positive study15
in which the inclusion criteria differed significantly from
other studies that have explored this treatment modality.
Specifically, the patients in Ballardie’s study were older, had
higher levels of serum creatinine, and had more severe renal
lesions on biopsy, as compared with other trials of cytotoxic
agents on patients with IgAN.16–18
Lack of consensus in definitions
Not only are both clinical presentation and response to
treatment highly variable in many glomerular diseases but the
spectrum of histopathology on renal biopsy may also be
diverse. Disagreement regarding histopathological classifica-
tion within a given disease entity is not uncommon. This
concept is well-exemplified by FSGS, in which a classification
system of five distinct variants has been proposed and widely
accepted.19 However, as noted by Meyrier,20,21 this system is
not without limitations as one renal biopsy may reveal
multiple variants simultaneously or, alternatively, may
indicate a different histological variant due to sampling
error. Others have proposed that the classification of primary
nephrotic diseases should incorporate specific pathophysio-
logical mechanisms.22
Further disagreement regarding disease categorization
centers around lumping and splitting. For example, some
investigators23 favor grouping tip variant FSGS as being
merely a variant of MCD. Other investigators have suggested
that MCD itself encompasses a heterogeneous group of
disorders and can be split into three distinct categories on the
basis of the presence or absence of hypoalbuminemia, overt
edema, and hypovolemia.24 This problem is further compli-
cated in children with nephrotic syndrome, wherein a renal
biopsy is typically not performed before initiating corticos-
teroids. Moreover, in some diseases, such as MN, the ability
of the renal histopathology to predict disease progression and
response to therapy is still debated.
The recognition of problems associated with the lack of
uniform and widely accepted histopathological classification
systems has been addressed by collaborative formulations in a
number of glomerular diseases, including LN,25 FSGS,19 and,
most recently, IgAN. Specifically, with regard to IgAN, lack of
consensus regarding its pathological classification was
addressed by the Working Group of the International
Nephropathy Network and the Renal Pathology Society.26
Renal biopsies from 265 adults and children with IgAN were
examined, and four specific pathological features were
identified as having an independent value in predicting the
renal outcome. In LN and FSGS, validation of these
classifications has been made in other populations. This
remains to be done in IgAN. It should be emphasized,
however, that one of the unique characteristics of the IgAN
classification scheme is that the pathological features
identified had significant predictive value even after account-
ing for all clinical indicators available at baseline, thereby
potentially becoming relevant factors in future study designs.
Hopefully, greater consensus in definition, including agree-
ment on classification systems as well as important clinical
end points, will encourage more robust collaborative efforts
(see below) and will allow for greater number of high quality
clinical trials.
Difficulty in recruiting patients
Many clinical trials investigating primary glomerular disease
use medications with narrow therapeutic indexes and
relatively high rates of toxicity, such as immunosuppressant
and immunomodulatory agents. Thus, it is likely that patients
may have greater reluctance to participate in such trials as
compared with trials of milder interventions, such as
angiotensin converting enzyme inhibitors in DN. Furthermore,
patients may be especially reluctant to participate in trials, such
as those studying primary glomerular disease, in which the
response to treatment is highly variable. This notion is especially
true for diseases, such as IgAN and MN, which often have a
slow progressive course. In addition, many patients as well as
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their physicians may feel it is better for an individual patient not
to enter a controlled trial but rather to wait and see the results
of such studies in other patients. Finally, those patients who are
most likely to progress in any given disease will be reluctant to
accept a placebo arm to any study given the wide array of
potential immune modulating agents available, which are Food
and Drug Administration (FDA) approved (albeit for other
indications).
Another major barrier to patient recruitment relates to
late diagnosis and late referral to a nephrologist. Earlier
referral of patients by general practitioners would greatly
increase the pool of potential subjects for enrollment in
prospective clinical trials. Moreover, there is increasing
evidence that early referral to a nephrologist, defined by
some as greater than a year before the initiation of dialysis,
results in improved patient survival.27,28 For this reason,
many have advocated for more intensified education of
non-nephrologist physicians regarding the importance of
early referral to a specialist.29 Although these studies
predominantly involved referrals for end-stage renal
disease evaluation among predialysis patients, it is not
unreasonable to extrapolate these findings to glomerular
disease and to expect improved outcomes with earlier referral
here as well.
High costs of RCTs
The increasing costs associated with performing RCTs is,
without a doubt, a major barrier. According to one report,30
the cost per patient for performing Phase 1, 2, and 3 clinical
trials in 2006 was $15,700, $19,300, and over $26,000,
respectively, and these costs continue to increase. For
example, the European clinical trials market in 2008 was
calculated to have a value of $32 billion, and is projected to
reach a value of $47 billion by 2012.31 Reasons for the
increasing costs associated with RCTs are numerous and
include expenditures related to: (1) salaries of research staff,
including study coordinators, research pharmacists, and
administrators; (2) complex statistical methodology requir-
ing expensive data management systems and highly-trained
statisticians (often at the PhD level); (3) increased docu-
mentation requirements; (4) independent data safety and
monitoring committees; (5) institutional review boards; and
(6) compliance with federal regulations, such as the Health
Insurance Portability and Accountability Act, making the
sharing of data both complex and expensive.32 Although
these costs and the problems associated with them are not
unique to nephrology, they are particularly challenging to our
field because of the limited funding of our national granting
agencies as compared with certain other fields.
Such prohibitive costs are one reason that large RCTs can
sometimes only be supported by pharmaceutical companies
or governmental funding agencies such as the NIH (National
Institutes of Health). Clearly the aim of industry-sponsored
trials is to bring a new drug to market or to broaden the
indication of an existing drug. For example, the ‘gold
standard’ medication for the treatment of LN for years was
intravenous cyclophosphamide, supported by data derived
from NIH ‘in-house’ studies. This medication never received
an FDA indication as therapy for LN. Thus, to get the FDA
approval for a new medication for LN, the new drug requires
evidence of superiority, not equivalency, to intravenous
cyclophosphamide. Pharmaceutical studies, designed to
obtain the FDA approval, must therefore adjust recruitment
and duration for the end point of superiority rather than the
easier aim of equivalency. Hence, the pharmaceutical-
sponsored aspreva lupus management study trial of MMF
versus intravenous cyclophosphamide needed to recruit 370
patients to attempt to establish the superiority of the former
over the latter regimen, and thereby broaden the indication
of MMF.33 In contrast, the Euro–Lupus group, funded by a
non-industry source (the European League Against Rheu-
matism), was able to show equivalency of two different
regimens of cyclophosphamide with only 90 patients.34 For
generic drugs, funding a large study essentially means that,
with rare exceptions, a governmental agency has to provide
the funding, as pharmaceutical companies have little
incentive to study and fine-tune optimal dosages for
medications, which are inexpensive and have already been
FDA-approved. An example is the FSGS clinical trial, which
compares generic cyclosporine with MMF and steroids in
patients with steroid-refractory FSGS.35
Lack of collaborative efforts
Finally, among diseases as rare as the primary glomerulo-
pathies, recruiting adequate number of subjects for high
quality RCTs is nearly impossible without robust collabora-
tive efforts. Nonetheless, these efforts are lacking. Among the
RCTs that evaluated MCD, for example, only 3/11 (27.3%)
were multi-center studies (2/9 in children and 1/2 in adults).
Consequently, among the six glomerular diseases studied in
this review, MCD represents the category with the fewest
number of enrolled subjects (Table 1). Furthermore, in cases
where single-center designs are used, lengthy recruitment
periods are often required and concepts of ideal management
may change during this time. Large, multi-center trials with
relatively short recruitment periods are much less likely be
affected by this problem.
The European Vasculitis Study Group,36 a partnership of
clinicians and researchers interested in clinical trials of
vasculitis, represents an ideal model of collaborative efforts
spanning across multiple nations. The group has been
successful in carrying out several, large RCTs evaluating
antineutrophil cytoplasmic-antibodies associated vasculitis,
including a study establishing the safety of azathioprine sub-
stitution for cyclophosphamide after remission (n¼ 155)37
and a study establishing the efficacy of plasma exchange in
improving rates of renal recovery (n¼ 100).38 Collaborative
efforts such as these should be enthusiastically echoed by
similar efforts in the investigation of glomerular disease. Such
efforts have been made in treating LN by combined efforts of
rheumatology and nephrology recruitment,33,39,40 however,
they are lacking in other areas of glomerular disease.
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WHY THE SHORTAGE OF META-ANALYSES IN GLOMERULAR
DISEASE?
The most obvious reason for the shortage of meta-analyses
among the primary glomerular diseases is the shortage of
corresponding RCTs. However, a second factor is also a
likely contributor: heterogeneity of clinical end points. Meta-
analyses depend on common end points to answer specific
clinical questions. When common clinical end points cannot
be found, meta-analyses are either not performed or
performed using a distribution-based approach, such as
Cohen’s standardized effect size, which is simply the mean
change divided by the s.d.41 However, this approach has
several limitations.42 Some investigators have suggested that
effect sizes may underestimate clinically important differ-
ences.43 Furthermore, effect sizes cannot be used to interpret
individual-based differences over time.44
Table 2 shows the wide heterogeneity among clinical
end points used in RCTs of glomerular disease. Even among
the end points of which significance is universally agreed
upon, such as proteinuria in the progression of kidney
disease, there is variability among studies regarding methods
of quantification and thresholds of clinical relevance. Despite
the heterogeneity of clinical end points, the focus of clinical
trials in glomerular disease often centers largely on
proteinuria and/or serum creatinine. End points such as
quality of life have been slow to be embraced, especially
as compared with other nephrology subspecialties such as
anemia of chronic kidney disease where an abundance of
literature exists on quality of life.42
RECOMMENDATIONS
(1) To facilitate greater numbers of high quality clinical trials
in glomerular disease, investigators and clinicians should
be encouraged to agree on common classification
systems of disease and common clinical end points. To
this point, a global non-profit foundation known as
Kidney Disease: Improving Global Outcomes is currently
conducting an evidence-based review process to establish
clinical practice guidelines for glomerulonephritis.45 The
guidelines are anticipated to be published in 2011 and
will include disease classification definitions and recom-
mendations for future research.
(2) To reconcile the contrasting aims and resources of studies
funded by pharmaceutical and non-industry sources,
collaboration between these two entities is to be strongly
encouraged. The funding provided by the industry
would ensure high quality research, with high numbers
of enrolled patients and adequate follow-up, whereas
peer-review agencies would lend credibility and aid in
the recruitment of patients through their connections
with national registries (see #3 below).
(3) Finally, given the small number of patients enrolled in
most studies of glomerular disease, national registries
should be created to facilitate collaborations across
institutions and across nations, as modeled by the
European Vasculitis Study Group. Such an endeavor
would have a greater chance of success if physicians feel a
greater obligation to register such patients in a central
databank, perhaps with the supervision and monitoring
by a governmental agency, thereby emulating various
cancer registry models.
In conclusion, until there is greater agreement on classifica-
tion systems of disease and greater collaboration among
investigators, it is unlikely that the fruit on the tree of
glomerular knowledge will germinate to its full potential.
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Table 2 | Heterogeneity of clinical end points used in RCTs of
renal disease
Composite outcomes
Progression to CKD or death; doubling of baseline serum creatinine or
progression to CKD stage IV or V or ESRD
Reduction in GFR
Serum creatinine, eGFR (MDRD, Cockgraft–Gault, iothalamate clearance,
creatinine clearance), or (99m) Tc-diethylenetriamine penta-acetic
renogram
Proteinuria
Spot microalbuminuria, spot urine protein/creatinine; 24 h urine protein
collection
Remission
Complete/partial: improvement in proteinuria, improvement/
stabilization of renal function, and improvement/stabilization of
systemic features.
Blood pressure (BP) control
Ambulatory BP, office BP, nocturnal BP, orthostatic hypotension,
number of antihypertensive medications
Glycemic control
Fasting blood glucose, hemoglobin A1c, and serum insulin and
C-peptide concentrations
Lipid profile
Low-density lipoprotein (LDL), high-density lipoprotein (HDL),
triglycerides (TGs), and cholesterol
Biomarkers/serology
Serum TNF-a, IGF-1, N-acetyl-b-glucosaminidase, type IV collagen, von
Willebrand factor, anti-double-stranded (ds) DNA antibodies; urinary
prostaglandin E2, urinary TGF-b
Histological/Pathological
Mesangial fractional volume (Mes/glom), nephrin expression, and
urinary podocytes
Health-related quality of life
SF-36, visual analog scale (VAS), and lupus symptom checklist
Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filteration
rate; ESRD, end-stage renal disease; GFR, glomerular filteration rate; IGF-1, insulin-
like growth factor 1; MDRD, modification of diet in renal disease; RCT, randomized
controlled trial; TGF-b, transforming growth factor b; TNF-a, tumor necrosis factor a.
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